학술논문
Advances in In Vitro Blood-Air Barrier Models and the Use of Nanoparticles in COVID-19 Research.
Document Type
Academic Journal
Author
Sevinc Ozdemir N; Acibadem University (ACU) Biomaterials A&R Center, Atasehir, Istanbul, Turkey.; Department of Medical Biotechnology, ACU Graduate School of Health Sciences, Istanbul, Turkey.; ACU Department of Pharmaceutical Basic Sciences, School of Pharmacy, Istanbul, Turkey.; Belyaev D; Fraunhofer Institute for Ceramic Technologies and Systems IKTS, Maria-Reiche Straße 2, Dresden, Germany.; Castro MN; Fraunhofer Institute for Ceramic Technologies and Systems IKTS, Maria-Reiche Straße 2, Dresden, Germany.; Balakin S; Fraunhofer Institute for Ceramic Technologies and Systems IKTS, Maria-Reiche Straße 2, Dresden, Germany.; Opitz J; Fraunhofer Institute for Ceramic Technologies and Systems IKTS, Maria-Reiche Straße 2, Dresden, Germany.; Wihadmadyatami H; Department of Tissue Engineering and Regenerative Medicine, Research Collaboration Center for Biomedical Scaffolds, National Research and Innovation Agency (BRIN) and Universitas Gadjah Mada (UGM), Bulaksumur, Yogyakarta, Indonesia.; Department of Anatomy, Faculty of Veterinary Medicine, Universitas Gadjah Mada (UGM), Bulaksumur, Yogyakarta, Indonesia.; Anggraeni R; Department of Tissue Engineering and Regenerative Medicine, Research Collaboration Center for Biomedical Scaffolds, National Research and Innovation Agency (BRIN) and Universitas Gadjah Mada (UGM), Bulaksumur, Yogyakarta, Indonesia.; Yucel D; Acibadem University (ACU) Biomaterials A&R Center, Atasehir, Istanbul, Turkey.; ACU Graduate Department of Biomaterials, Istanbul, Turkey.; Department of Histology and Embryology, ACU School of Medicine, Istanbul, Turkey.; Kenar H; Acibadem University (ACU) Biomaterials A&R Center, Atasehir, Istanbul, Turkey.; ACU Graduate Department of Biomaterials, Istanbul, Turkey.; ACU Faculty of Engineering Sciences, Department of Biomedical Engineering, Istanbul, Turkey.; Beshchasna N; Fraunhofer Institute for Ceramic Technologies and Systems IKTS, Maria-Reiche Straße 2, Dresden, Germany.; Ana ID; Department of Tissue Engineering and Regenerative Medicine, Research Collaboration Center for Biomedical Scaffolds, National Research and Innovation Agency (BRIN) and Universitas Gadjah Mada (UGM), Bulaksumur, Yogyakarta, Indonesia.; Department of Dental Biomedical Sciences, Faculty of Dentistry, Universitas Gadjah Mada (UGM), Bulaksumur, Yogyakarta, Indonesia.; Hasirci V; Acibadem University (ACU) Biomaterials A&R Center, Atasehir, Istanbul, Turkey.; ACU Graduate Department of Biomaterials, Istanbul, Turkey.; ACU Faculty of Engineering Sciences, Department of Biomedical Engineering, Istanbul, Turkey.; BIOMATEN, METU Ctr. of Excellence in Biomaterials and Tissue Engineering, Ankara, Turkey.
Source
Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 101466660 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1937-3376 (Electronic) Linking ISSN: 19373368 NLM ISO Abbreviation: Tissue Eng Part B Rev Subsets: MEDLINE
Subject
Language
English
Abstract
Respiratory infections caused by coronaviruses (CoVs) have become a major public health concern in the past two decades as revealed by the emergence of SARS-CoV in 2002, MERS-CoV in 2012, and SARS-CoV-2 in 2019. The most severe clinical phenotypes commonly arise from exacerbation of immune response following the infection of alveolar epithelial cells localized at the pulmonary blood-air barrier. Preclinical rodent models do not adequately represent the essential genetic properties of the barrier, thus necessitating the use of humanized transgenic models. However, existing monolayer cell culture models have so far been unable to mimic the complex lung microenvironment. In this respect, air-liquid interface models, tissue engineered models, and organ-on-a-chip systems, which aim to better imitate the infection site microenvironment and microphysiology, are being developed to replace the commonly used monolayer cell culture models, and their use is becoming more widespread every day. On the contrary, studies on the development of nanoparticles (NPs) that mimic respiratory viruses, and those NPs used in therapy are progressing rapidly. The first part of this review describes in vitro models that mimic the blood-air barrier, the tissue interface that plays a central role in COVID-19 progression. In the second part of the review, NPs mimicking the virus and/or designed to carry therapeutic agents are explained and exemplified.